Group One Trading
ABCL icon

Group One Trading’s AbCellera Biologics ABCL Stock Holding History

Group One Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Sell
385,200
-72,900
-16% -$262K ﹤0.01% 2446
2025
Q4 		$1.57M Buy
458,100
+82,100
+22% +$366K ﹤0.01% 2487
2025
Q3 		$1.89M Buy
376,000
+216,200
+135% +$953K ﹤0.01% 2376
2025
Q2 		$548K Buy
159,800
+52,200
+49% +$130K ﹤0.01% 3316
2025
Q1 		$240K Buy
107,600
+18,500
+21% +$53.1K ﹤0.01% 3835
2024
Q4 		$261K Buy
89,100
+38,200
+75% +$106K ﹤0.01% 3729
2024
Q3 		$132K Buy
50,900
+1,800
+4% +$4.99K ﹤0.01% 3958
2024
Q2 		$145K Buy
49,100
+3,000
+7% +$11.4K ﹤0.01% 3661
2024
Q1 		$209K Sell
46,100
-273,300
-86% -$1.39M ﹤0.01% 3526
2023
Q4 		$1.82M Buy
319,400
+39,700
+14% +$184K ﹤0.01% 1951
2023
Q3 		$1.29M Sell
279,700
-28,000
-9% -$170K ﹤0.01% 2022
2023
Q2 		$1.99M Sell
307,700
-46,000
-13% -$314K 0.01% 1716
2023
Q1 		$2.67M Sell
353,700
-135,700
-28% -$1.23M 0.01% 1299
2022
Q4 		$4.96M Sell
489,400
-157,600
-24% -$1.82M 0.01% 1153
2022
Q3 		$6.4M Buy
647,000
+381,000
+143% +$4.18M 0.01% 987
2022
Q2 		$2.83M Sell
266,000
-390,500
-59% -$3.31M ﹤0.01% 1734
2022
Q1 		$6.4M Sell
656,500
-381,900
-37% -$3.62M 0.01% 1343
2021
Q4 		$14.8M Buy
1,038,400
+241,700
+30% +$3.67M 0.01% 836
2021
Q3 		$16M Buy
796,700
+662,400
+493% +$11.7M 0.02% 748
2021
Q2 		$2.96M Buy
134,300
+126,400
+1,600% +$3.49M ﹤0.01% 2230
2021
Q1 		$268K Buy
+7,900
New +$315K ﹤0.01% 4704

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading's ABCL Position: Q1 2026 in Review

Group One Trading increased its AbCellera Biologics (ABCL) stake by 85% in Q1 2026, buying an estimated $396K and bringing the position to 239,133 shares worth $835K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Group One Trading first reported a position in ABCL in Q2 2021 and has held it in 18 quarters since. The position peaked at $1.21M in Q4 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Group One Trading held 239,133 shares of AbCellera Biologics worth $835K as of Q1 2026.
  • Group One Trading bought 110,134 AbCellera Biologics shares in Q1 2026, an estimated $396K.
  • AbCellera Biologics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2878 holding.
  • Group One Trading first reported a position in AbCellera Biologics in Q2 2021 and has held it in 18 quarters since.
  • Group One Trading's AbCellera Biologics position peaked at $1.21M in Q4 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.